CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model

Prexasertib (LY2606368) is a potent and selective small molecule inhibitor of cell-cycle checkpoint CHK1 and CHK2 protein kinases and is currently under clinical evaluation for treatment of pediatric malignancies. As a candidate therapy for pediatric Group 3 medulloblastoma (G3MB), prexasertib CNS p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Pharm Sci
Hlavní autoři: Campagne, Olivia, Davis, Abigail, Maharaj, Anil R., Zhong, Bo, Stripay, Jennifer, Farmer, Dana, Roussel, Martine F., Stewart, Clinton F.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6925336/
https://ncbi.nlm.nih.gov/pubmed/31669383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejps.2019.105106
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky